Head and Neck Carcinoma Clinical Trials & Research at Providence Medical Group
Head and neck cancers start in the tissues and organs of the head and neck
and include cancers of the larynx (voice box), throat, lips, mouth, nose,
and salivary glands. Most head and neck cancers are squamous cell carcinomas
and begin in the moist tissues that line the mouth, nose and throat. Tobacco
use, heavy alcohol use, and infection with the human papillomavirus (HPV)
increase your risk of head and neck cancer.
Providence Medical Group is currently enrolling patients for the following
head and neck carcinoma clinical trial:
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy
Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma
(MK-3475-689)
Treatment agent: Pembrolizumab
PI: Ian Anderson, MD
Study Coordinator: Melissa Phillips // Melissa.Phillips2@stjoe.org// (707)
521-3833 ext. 1313
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT03765918?term=NCT03765918&draw=2&rank=1
Merck
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as
Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant
Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and
Neck Squamous Cell Carcinoma (KEYNOTE-689)
Treatment agent: Pembrolizumab + standard of care radiation therapy
PI:
Ian Anderson, MD
Study Coordinator: Tracy Foster //
Tracy.Foster@stjoe.org // (707) 521-3836
Resources and Links:
clinicaltrials.gov NCT No: NCT03765918
Study of Magrolimab Combination Therapy in Participants With Head and Neck
Squamous Cell Carcinoma(GS 5916)
Treatment agent: Magrolimab + Pembrolizumab, or 5-FU, Cisplatin, Carboplatin,
or Docetael
PI:
Ian Anderson, MD
Study Coordinator: Melissa Phillips // Melissa.Phillips2@stjoe.org// (707)
521-3833 ext. 1313
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT04854499?term=NCT04854499&draw=2&rank=1
Gilead Sciences, Inc.
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy
Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma
(MK-3475-689)
Treatment agent: Pembrolizumab
PI:
Ian Anderson, MD
Study Coordinator: Melissa Phillips // Melissa.Phillips2@stjoe.org// (707)
521-3833 ext. 1313
Resources and Links:
https://clinicaltrials.gov/ct2/show/NCT03765918?term=NCT03765918&draw=2&rank=1
Merck
A Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and
Safety Trial of Single Cycle Tetrodotoxin in the Treatment of Chemotherapy
Induced Neuropathic Pain
Treatment agent: Tetrodotoxin
PI:
Ian Anderson, MD
Study Coordinator: Melissa Phillips // Melissa.Phillips2@stjoe.org// (707)
521-3833 ext. 1313
Resources and Links:
https://clinicaltrials.gov/ct2/show/NCT05359133?term=NCT05359133&draw=2&rank=1
Wex Pharmacueticals